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bstract
he American College of Cardiology Foundation (ACCF)
nd the American Society of Echocardiography (ASE) to-
ether with key specialty and subspecialty societies, conducted
n appropriateness review for stress echocardiography. The
eview assessed the risks and benefits of stress echocardiogra-
hy for several indications or clinical scenarios and scored them
n a scale of 1 to 9 (based upon methodology developed by the
CCF to assess imaging appropriateness). The upper range (7o 9) implies that the test is generally acceptable and is a
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March 18, 2008:1127–47 Appropriateness Criteria for Echocardiographyeasonable approach, and the lower range (1 to 3) implies that
he test is generally not acceptable and is not a reasonable
pproach. The midrange (4 to 6) indicates a clinical scenario for
hich the indication for a stress echocardiogram is uncertain.
The indications for this review were drawn from common
pplications or anticipated uses, as well as from current clinical
ractice guidelines. Use of stress echocardiography for risk
ssessment in patients with coronary artery disease (CAD) was
iewed favorably, while routine repeat testing and general
creening in certain clinical scenarios were viewed less favor-
bly. It is anticipated that these results will have a significant
mpact on physician decision making and performance, reim-
ursement policy, and will help guide future research.
reface
n an effort to respond to the need for the rational use of
maging services in the delivery of high quality care, the
merican College of Cardiology Foundation (ACCF) has
ndertaken a process to determine the appropriateness of
ardiovascular imaging for selected patient indications.
Appropriateness criteria publications reflect an ongoing
ffort by the ACCF to critically and systematically create,
eview, and categorize clinical situations where diagnostic tests
nd procedures are utilized by physicians caring for patients
ith cardiovascular diseases. The process is based on a current
nderstanding of the technical capabilities of the imaging
odalities examined. Although not intended to be entirely
omprehensive, the indications are meant to identify common
cenarios encompassing the majority of contemporary practice.
iven the breadth of information they convey, the indications
o not directly correspond to the Ninth Revision of the
nternational Classification of Diseases (ICD-9) system.
The ACCF believes that careful blending of a broad
ange of clinical experiences and available evidence-based
nformation will help guide a more efficient and equitable
llocation of health care resources in cardiovascular imaging.
he ultimate objective of appropriateness criteria is to improve
atient care and health outcomes in a cost-effective manner but
s not intended to ignore ambiguity and nuance intrinsic to
linical decision making. Local parameters, such as the avail-
bility or quality of equipment or personnel, may influence the
election of appropriate imaging procedures. Thus, appropri-
teness criteria should not be considered substitutes for sound
linical judgment and practice experience.
The ACCF appropriateness criteria process itself is also
volving. In the current iteration, Technical Panel members
ere asked to rate indications for stress echocardiography in
manner independent and irrespective of prior ACCF
atings for similar diagnostic stress imaging modalities such
s single-photon emission computed tomography myocar-
ial perfusion imaging (SPECT MPI) (1), cardiac com-
uted tomography (CT), or cardiac magnetic resonance (2).
iven the iterative nature of the process, readers areounseled not to compare too closely the individual appro-
e
driateness ratings among modalities rated at different times
ver the past 2 years. A “cross-modality” evaluation of the
ppropriateness of multiple imaging techniques will be
ndertaken in the near future. This evaluation should more
irectly answer questions about the strengths of each mo-
ality relative to alternatives for various clinical scenarios.
In developing these criteria the Appropriateness Criteria
echnical Panel was asked to assess whether the use of the test
or each indication is appropriate, uncertain, or inappropriate;
hey were provided the following definition of appropriateness:
An appropriate imaging study is one in which the expected
ncremental information, combined with clinical judgment,
xceeds the expected negative consequences* by a sufficiently
ide margin for a specific indication that the procedure is
enerally considered acceptable care and a reasonable ap-
roach for the indication.
The Technical Panel scores each indication as follows:
Score 7 to 9
Appropriate test for specific indication (test is generally
cceptable and is a reasonable approach for the indication).
Score 4 to 6
Uncertain for specific indication (test may be generally
cceptable and may be a reasonable approach for the
ndication). (Uncertainty also implies that more research
nd/or patient information is needed to classify the indica-
ion definitively.)
Score 1 to 3
Inappropriate test for that indication (test is not generally
cceptable and is not a reasonable approach for the indication).
The contributors acknowledge that the division of these
cores into 3 categories of appropriateness is somewhat
rbitrary and that the numeric designations should be
iewed as a continuum. The contributors also recognize
iversity in clinical opinion for particular clinical scenarios.
herefore, scores in the intermediate level of appropriate-
ess should be labeled “uncertain,” as critical patient or
esearch data are lacking and should be a prompt to the field
o conduct definitive research investigation. It is anticipated
hat the appropriateness criteria reports will require updates
s further data are generated and information from the
mplementation of the criteria is accumulated.
To prevent bias in the scoring process, the Technical Panel
eliberately was not comprised solely of specialists in the
articular procedure under evaluation. Specialists, while offer-
ng important clinical and technical insights, might have a
atural tendency to rate the indications within their specialty as
ore appropriate than nonspecialists. In addition, care was
aken in providing objective, nonbiased information, including
uidelines and key references, to the Technical Panel.
Negative consequences include the risks of the procedure (i.e., radiation or contrast
xposure) and the downstream impact of poor test performance such as delay in
iagnosis (false negatives) or inappropriate diagnosis (false positives).
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roup with a wide range of skills and insights, for a
houghtful and thorough deliberation of the merits of stress
chocardiography for various indications. In addition to our
hanks to the Technical Panel for their dedicated work and
eview, we would like to offer special thanks to William
rmstrong, MD, Christopher Kramer, MD, Robert Mc-
amara, MD, and Catherine Otto, MD, for reviewing the
raft indications; to Peggy Christiansen, the ACC librarian
or her comprehensive literature searches; to Karen Caruth,
ho continually drove the process forward, and to ACCF
ast President Pamela Douglas, MD, MACC, FAHA,
ASE, for her insight and leadership.
Eric D. Peterson, MD, MPH, FACC, FAHA
Moderator, Stress Echocardiography Technical Panel
Ralph G. Brindis, MD, MPH, FACC
Chair, ACCF Appropriateness Criteria Task Force
ntroduction
his report addresses the appropriateness of stress echocar-
iography. The improvement in the test characteristics of
tress echocardiography in recent years has increased its
tility for detection and risk assessment of ischemic heart
isease. Similar to other forms of stress imaging testing,
tress echocardiography can help more clearly define cardio-
ascular risk for a patient, but also creates opportunities for
veruse and misuse in patients who may not obtain a
enefit, or who could have been medically managed effec-
ively without the addition of the test. In particular, inap-
ropriate use may be costly and may prompt potentially
armful and costly downstream testing and treatment such
s unwarranted coronary revascularization or unnecessary
epeat follow-up. Concerns about inappropriate use exist
mong those who pay for these services and clinical leaders
ho evaluate the effectiveness of testing.
ethods
he indications included in this review are purposefully
road, and they comprise a wide array of cardiovascular
igns and symptoms as well as clinical judgment as to the
ikelihood of cardiovascular findings.
A detailed description of the methods used for ranking of
he selected clinical indications is outlined in Appendix B
nd is also found more generally in a previous publication,
ACCF Proposed Method for Evaluating the Appropriate-
ess of Cardiovascular Imaging” (3). Briefly, this process
ombines evidence-based medicine and practice experience
y engaging a technical panel in a modified Delphi exercise.
he panel first rated indications independently. Then the
anel was convened for a face-to-face meeting for discussion
f each indication. At this meeting, panel members were
rovided with their scores and a blinded summary of their
eers’ scores. After the consensus meeting, panel members
†
fere then asked to independently provide their final scores
or each indication.
The level of agreement among panelists as defined by
AND (4) was analyzed based on the BIOMED rule for a
anel of 14 to 16. As such, agreement was defined as an
ndication where 4 or fewer panelists’ ratings fell outside the
-point region containing the median score. Disagreement
as defined as where at least 5 panelists’ ratings fell in both
he appropriate and the inappropriate categories.
eneral Assumptions for Stress Echocardiography
o prevent any nuances of interpretation, all indications
ere considered with the following important assumptions:
. All indications are assumed to apply to adult patients (18
years of age or older).
. The test is performed and interpreted by qualified
individuals in facilities that are proficient in the imaging
technique (5–8).
The indications were constructed by echocardiography ex-
erts and modified on the basis of discussions among the Task
orce and feedback from independent reviewers and the
echnical Panel. Wherever possible, indications were mapped
o relevant clinical guidelines and key publications/references
Online Appendix at http://content.onlinejacc.org).
The Technical Panel was comprised of clinician experts,
ome with backgrounds in cardiac imaging and others with
xperience in general cardiovascular medicine, cardiac sur-
ery, critical care medicine, emergency medicine, health ser-
ices research, and health plan administration.† Panelists were
nstructed to incorporate in their deliberations several assump-
ions specifically for stress echocardiography, including:
. All standard echocardiographic techniques for image acqui-
sition, including imaging protocols, are available for each
indication, and stress echocardiography has a sensitivity and
specificity similar to those found in the published literature.
. For all stress imaging, the mode of stress testing is assumed
to be exercise for patients able to exercise. For patients
unable to exercise, it is assumed that dobutamine is used for
echocardiographic stress testing. Further background on
the rationale for the assumption of exercise stress is available
in the ACC/AHA 2002 Guideline Update for Exercise
Stress Testing (9). Any indications including a specific
mode of stress are labeled as such.
. Preoperative evaluation includes procedures such as or-
gan transplantation.
bbreviations
CS  acute coronary syndrome
I aortic insufficiency
ABG  coronary artery bypass grafting surgery
AD coronary artery diseaseFull detail about the backgrounds of the members of the Technical Panel can be
ound in Appendix C.
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T  computed tomography
CG  electrocardiogram
F  heart failure
V  left ventricular
ET  estimated metabolic equivalents of exercise
I  myocardial infarction
R  mitral regurgitation
CI  percutaneous coronary intervention
PECT MPI  single-photon emission computed tomog-
aphy myocardial perfusion imaging
A/NSTEMI  unstable angina (UA) and non-ST-
levation myocardial infarction (NSTEMI)
esults of Ratings
he final ratings for stress echocardiography (Tables 1 to
0) are listed by indication sequentially as obtained from
econd round rating sheets submitted by each panelist.
dditionally, the indications are presented by Appropriate-
ess Category (Tables 11 to 13).
Definitions used by the Technical Panel can be found inf the mean absolute deviation from the median and level of
greement of rankings for each indication, can be found in
he Online Appendix at http://content.onlinejacc.org.
For the 51 indications for the use of stress echocardiog-
aphy, 22 were found to be appropriate, 10 were uncertain,
nd 19 were considered inappropriate.
Typically, there was greater variability in scores of indi-
ations defined as uncertain, suggesting wide variation in
pinion. A number of indications failed to meet the above
efinition of agreement. Still, there were no uncertain
ndications where the panel held such opposing viewpoints
hat the indication was labeled as one for which the panel
isagreed. There was generally less variation for the indica-
ions labeled as either appropriate or inappropriate, with
8.8% and 79.0%, respectively, showing agreement as pre-
iously defined. Disagreement did not occur for any of the
ndications ultimately defined as appropriate or inappropri-
te. Finally, as prior research has found that, in general, the
est operating characteristics of stress echocardiography and
PECT MPI imaging are similar, we also provide the
eaders with an asterisk where there were discordances
etween similar indications rated inappropriate for stress
chocardiography and those previously rated uncertain forppendix A. Supplemental tables, including documentation SPECT MPI.
tress Echocardiography Appropriateness Criteria (by Indication)
able 1. Detection of CAD/Risk Assessment: Symptomatic
Indication
Appropriateness
Score (1–9)
Evaluation of Chest Pain Syndrome or Anginal Equivalent
1. ● Low pre-test probability of CAD
● ECG interpretable AND able to exercise
I (3)
2. ● Low pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (7)
3. ● Intermediate pre-test probability of CAD
● ECG interpretable AND able to exercise
A (7)
4. ● Intermediate pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (9)
5. ● High pre-test probability of CAD
● Regardless of ECG interpretability and ability to exercise
A (7)
6. ● Prior stress ECG test is uninterpretable or equivocal A (8)
Acute Chest Pain
7. ● Intermediate pre-test probability of CAD
● ECG–no dynamic ST changes AND serial cardiac enzymes negative
A (8)
8. ● High pre-test probability of CAD
● ECG–ST elevation
I (1)
New-Onset/Diagnosed Heart Failure With Chest Pain Syndrome or Anginal Equivalent
9. ● Intermediate pre-test probability
● Normal LV systolic function
A (8)
10. ● LV systolic function U (5)
T*
w
s
T
D
*
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Appropriateness Criteria for Echocardiography March 18, 2008:1127–47able 2. Detection of CAD and Risk Assessment: Asymptomatic (Without Chest Pain Syndrome or Anginal Equivalent)
Indication
Appropriateness
Score (1–9)
General Patient Populations
11. ● Low CHD risk (Framingham risk criteria) I (1)
12. ● Moderate CHD risk (Framingham)
● ECG Interpretable
I (3)*
13. ● High CHD risk (Framingham) U (6)
The ranking of this indication as inappropriate is different from that given to similar but not identical indications in previously published appropriateness criteria. The ratings were done in accordance
ith established ACCF methodology. Furthermore, the Technical Panel for each modality operated independently without allowance and with discouragement for intermodality comparisons. Discrepant
cores may be related to rating variability, differing Technical Panel composition, maturation of the appropriatness criteria process, or perceived differences in appropriateness.able 3. Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With
efined Comorbidities
Indication
Appropriateness
Score (1–9)
New-Onset or Diagnosed Heart Failure or LV Systolic Dysfunction
14. ● Moderate CHD risk (Framingham)
● No prior CAD evaluation
● Normal LV systolic function
A (7)
15 ● Moderate CHD risk (Framingham)
● No prior CAD evaluation
● Abnormal LV systolic dysfunction
U (5)
Valvular Heart Disease Requiring Valve Surgery
16. ● Moderate CHD risk (Framingham) I (3)
New-Onset Atrial Fibrillation
17. ● Low CHD risk (Framingham)
● Part of the evaluation
I (2)*
18. ● Moderate to high CHD risk (Framingham)
● Part of the evaluation
A (7)
Nonsustained Ventricular Tachycardia
19. ● Moderate to high CHD risk (Framingham)
● Stress echo using exercise stress only
A (7)
The ranking of this indication as inappropriate is different from that given to similar but not identical indications in previously published appropriateness criteria. The ratings were done in accordance
ith established ACCF methodology. Furthermore, the Technical Panel for each modality operated independently without allowance and with discouragement for intermodality comparisons. Discrepant
cores may be related to rating variability, differing Technical Panel composition, maturation of the appropriatness criteria process, or perceived differences in appropriateness.able 4. Risk Assessment With Prior Test Results
Indication
Appropriateness
Score (1–9)
Asymptomatic OR Stable Symptoms, Normal Prior Stress Imaging Study
20. ● High CHD risk
● Repeat stress echo study annually
I (2)
21. ● High CHD risk
● Repeat stress echo study after 2 years or greater
U (5)
Known CAD: Asymptomatic OR Stable Symptoms, Abnormal Catheterization OR Abnormal Prior Stress Imaging Study
22. ● Assessment of severity of ischemia (CAD)
● Less than 1 year to evaluate medically managed patients
I (2)
23. ● Assessment of severity of ischemia (CAD)
● Greater than or equal to 2 years to evaluate medically managed patients
U (5)
Worsening Symptoms: Abnormal Catheterization OR Abnormal Prior Stress Imaging Study
24. ● Re-evaluation of medically managed patients A (8)
Asymptomatic Prior Coronary Calcium Agatston Score
25. ● Agatston score greater than or equal to 400 A (7)
26. ● Agatston score less than 100 I (1)
Chest Pain Syndrome or Anginal Equivalent
27. ● Coronary artery stenosis of unclear significance (cardiac catheterization or CT angiography) A (8)
T†
T
T
*
w
s
T
1133JACC Vol. 51, No. 11, 2008 Douglas et al.
March 18, 2008:1127–47 Appropriateness Criteria for Echocardiographyable 5. Risk Assessment: Preoperative Evaluation for Noncardiac Surgery†
Indication
Appropriateness
Score (1–9)
Low-Risk Surgery
28. ● Preoperative evaluation for noncardiac surgery risk assessment
● Minor or intermediate clinical risk predictors
I (1)
Intermediate-Risk Surgery
29. ● Poor exercise tolerance (less than or equal to 4 METs)
● Minor or no clinical risk predictors
I (2)
30. ● Poor exercise tolerance (less than or equal to 4 METs)
● Intermediate clinical risk predictors
A (7)
High-Risk Nonemergent Surgery
31. ● Poor exercise tolerance (less than 4 METs) A (8)
32. ● Asymptomatic up to 1 year after normal catheterization, noninvasive test, or previous
revascularization
I (1)See discussion and appendix for changes in the revised 2007 ACC/AHA Perioperative Guidelines relevant to these indications (10).able 6. Risk Assessment: Following Acute Coronary Syndrome
Indication
Appropriateness
Score (1–9)
UA/NSTEMI—No Recurrent Symptoms or Signs of Heart Failure
33. ● Not planning to undergo early catheterization A (8)
Acute Coronary Syndrome—Asymptomatic Post-Revascularization (PCI or CABG)
34. ● Routine evaluation prior to hospital discharge I (1)able 7. Risk Assessment: Post-Revascularization (PCI or CABG)
Indication
Appropriateness
Score (1–9)
Symptomatic
35. ● Evaluation of chest pain syndrome
● Not in the early post-procedure period
A (8)
Asymptomatic
36. ● Less than 5 years after CABG I (2)*
37. ● Asymptomatic (e.g., silent ischemia) prior to previous revascularization
● Greater than or equal to 5 years after CABG
U (6)
38. ● Symptomatic prior to previous revascularization
● Greater than or equal to 5 years after CABG
U (5)
39. ● Asymptomatic (e.g., silent ischemia) prior to previous revascularization
● Less than 2 years after PCI
I (3)*
40. ● Symptomatic prior to previous revascularization
● Less than 2 years after PCI
I (2)
41. ● Asymptomatic (e.g., silent ischemia) prior to previous revascularization
● Greater than or equal to 2 years after PCI
U (5)
The ranking of this indication as inappropriate is different from that given to similar but not identical indications in previously published appropriateness criteria. The ratings were done in accordance
ith established ACCF methodology. Furthermore, the Technical Panel for each modality operated independently without allowance and with discouragement for intermodality comparisons. Discrepant
cores may be related to rating variability, differing Technical Panel composition, maturation of the appropriateness criteria process, or perceived differences in appropriateness.able 8. Assessment of Viability/Ischemia
Indication
Appropriateness
Score (1–9)
Ischemic Cardiomyopathy, Assessment of Viability/Ischemia
42. ● Known CAD on catheterization
● Patient eligible for revascularization
A (8)
ST
T
T
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able 9. Stress Study for Hemodynamics (Includes Doppler During Stress)
Indication
Appropriateness
Score (1–9)
Valvular Stenosis
43. ● Evaluation of equivocal aortic stenosis
● Evidence of low cardiac output
● Use of dobutamine
A (8)
44. ● Asymptomatic individuals
● Mild to moderate mitral stenosis
U (5)
45. ● Symptomatic individuals
● Mild mitral stenosis
A (7)
46. ● Severe aortic or mitral stenosis I (2)
47. ● Asymptomatic severe AI or MR
● LV size and function not meeting surgical criteria
A (7)
48. ● Severe AI or MR
● Symptomatic or with severe LV enlargement or LV systolic dysfunction
I (2)
Pulmonary Hypertension
49. ● Suspected pulmonary hypertension
● Normal or indeterminate resting echo study
U (5)
able 10. Contrast Use
Indication
Appropriateness
Score (1–9)
Use of Contrast With Stress Echo
50. ● Routine use of contrast
● All segments visualized on noncontrast images
I (1)
51. ● Selective use of contrast
● 2 or more contiguous segments are NOT seen on noncontrast images
A (8)
able 11. Appropriate Indications (Median Score 7 to 9)
Indication
Appropriateness
Score (1–9)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome or Anginal Equivalent
2. ● Low pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (7)
3. ● Intermediate pre-test probability of CAD
● ECG interpretable AND able to exercise
A (7)
4. ● Intermediate pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (9)
5. ● High pre-test probability of CAD
● Regardless of ECG interpretability and ability to exercise
A (7)
6. ● Prior stress ECG test is uninterpretable or equivocal A (8)
Detection of CAD: Symptomatic—Acute Chest Pain
7. ● Intermediate pre-test probability of CAD
● ECG—no dynamic ST changes AND serial cardiac enzymes negative
A (8)
Detection of CAD: Symptomatic—New-Onset/Diagnosed Heart Failure With Chest Pain Syndrome or Anginal Equivalent
9. ● Intermediate pre-test probability
● Normal LV systolic function
A (8)
Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With Defined Comorbidities—
New-Onset or Diagnosed Heart Failure or LV Systolic Dysfunction
14. ● Moderate CHD risk (Framingham)
● No prior CAD evaluation
● Normal LV systolic function
A (7)
T1135JACC Vol. 51, No. 11, 2008 Douglas et al.
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Indication
Appropriateness
Score (1–9)
Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With Defined Comorbidities—
New-Onset Atrial Fibrillation
18. ● Moderate to high CHD risk (Framingham)
● Part of the evaluation
A (7)
Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With Defined Comorbidities—
Nonsustained Ventricular Tachycardia
19. ● Moderate to high CHD risk (Framingham)
● Stress echo using exercise stress only
A (7)
Risk Assessment with Prior Test Results—Worsening Symptoms: Abnormal Catheterization OR Abnormal Prior Stress Imaging Study
24. ● Re-evaluation of medically managed patients A (8)
Risk Assessment With Prior Test Results—Asymptomatic, Prior Coronary Calcium Agatston Score
25. ● Agatston score greater than or equal to 400 A (7)
Risk Assessment With Prior Test Results—Chest Pain Syndrome or Anginal Equivalent
27. ● Coronary artery stenosis of unclear significance (cardiac catheterization or CT angiography) A (8)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery—Intermediate-Risk Surgery
30. ● Poor exercise tolerance (less than or equal to 4 METs)
● Intermediate clinical risk predictors
A (7)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery—High-Risk Nonemergent Surgery
31. ● Poor exercise tolerance (less than 4 METs) A (8)
Risk Assessment: Following Acute Coronary Syndrome–UA/NSTEMI—No Recurrent Symptoms or Signs of Heart Failure
33. ● Not planning to undergo early catheterization A (8)
Risk Assessment: Post-Revascularization (PCI or CABG)—Symptomatic
35. ● Evaluation of chest pain syndrome
● Not in the early post-procedure period
A (8)
Ischemic Cardiomyopathy Assessment of Viability/Ischemia—Ischemic Cardiomyopathy, Assessment of Viability/Ischemia
42. ● Known CAD on catheterization
● Patient eligible for revascularization
A (8)
Stress Study for Hemodynamics (Includes Doppler During Stress)—Valvular Stenosis
43. ● Evaluation of equivocal aortic stenosis
● Evidence of low cardiac output
● Use of dobutamine
A (8)
45. ● Symptomatic individuals
● Mild mitral stenosis
A (7)
47. ● Asymptomatic severe AI or MR
● LV size and function not meeting surgical criteria
A (7)
Contrast Use—Use of Contrast With Stress Echo
51. ● Selective use of contrast
● 2 or more contiguous segments are NOT seen on noncontrast images
A (8)
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Indication
Appropriateness
Score (1–9)
Detection of CAD: Symptomatic—New-Onset/Diagnosed Heart Failure With Chest Pain Syndrome or Anginal Equivalent
10. ● Intermediate pre-test probability
● Abnormal LV systolic function
U (5)
Detection of CAD and Risk Assessment: Asymptomatic (Without Chest Pain Syndrome or Anginal Equivalent) General Patient Populations
13. ● High CHD risk (Framingham) U (6)
Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With Defined Comorbidities—
New-Onset or Diagnosed Heart Failure or LV Systolic Dysfunction
15. ● Moderate CHD risk (Framingham)
● No prior CAD evaluation
● Abnormal LV systolic dysfunction
U (5)
Risk Assessment With Prior Test Results—Asymptomatic OR Stable Symptoms, Normal Prior Stress Imaging Study
21. ● High CHD risk
● Repeat stress echo study after 2 years or greater
U (5)
Risk Assessment With Prior Test Results—Known CAD: Asymptomatic OR Stable Symptoms, Abnormal Catheterization OR
Abnormal Prior Stress Imaging Study
23. ● Assessment of severity of ischemia (CAD)
● Greater than or equal to 2 years to evaluate medically managed patients
U (5)
Risk Assessment: Post-Revascularization (PCI or CABG)—Asymptomatic
37. ● Asymptomatic (e.g., silent ischemia) prior to previous revascularization
● Greater than or equal to 5 years after CABG
U (6)
38. ● Symptomatic prior to previous revascularization
● Greater than or equal to 5 years after CABG
U (5)
41. ● Asymptomatic (e.g., silent ischemia) prior to previous revascularization
● Greater than or equal to 2 years after PCI
U (5)
Stress Study for Hemodynamics (Includes Doppler During Stress)—Valvular Stenosis
44. ● Asymptomatic individuals
● Mild to moderate mitral stenosis
U (5)
Stress Study for Hemodynamics (Includes Doppler During Stress)—Pulmonary Hypertension
49. ● Suspected pulmonary hypertension
● Normal or indeterminate resting echo study
U (5)
T*
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Indication
Appropriateness
Score (1–9)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome or Anginal Equivalent
1. ● Low pre-test probability of CAD
● ECG interpretable AND able to exercise
I (3)
Detection of CAD: Symptomatic—Acute Chest Pain
8. ● High pre-test probability of CAD
● ECG ST-elevation
I (1)
Detection of CAD and Risk Assessment: Asymptomatic (Without Chest Pain Syndrome or Anginal Equivalent)—General Patient Populations
11. ● Low CHD risk (Framingham risk criteria) I (1)
12. ● Moderate CHD risk (Framingham)
● ECG interpretable
I (3)*
Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With Defined Comorbidities—
Valvular Heart Disease Requiring Valve Surgery
16. ● Moderate CHD risk (Framingham) I (3)
Detection of CAD/Risk Assessment: Without Chest Pain Syndrome or Anginal Equivalent in Patient Populations With Defined Comorbidities—
New-Onset Atrial Fibrillation
17. ● Low CHD risk (Framingham)
● Part of the evaluation
I (2)*
Risk Assessment With Prior Test Results—Asymptomatic OR Stable Symptoms, Normal Prior Stress Imaging Study
20. ● High CHD risk
● Repeat stress echo study annually
I (2)
Risk Assessment With Prior Test Results—Known CAD: Asymptomatic OR Stable Symptoms, Abnormal Catheterization OR
Abnormal Prior Stress Imaging Study
22. ● Assessment of severity of ischemia (CAD)
● Less than 1 year to evaluate medically managed patients
I (2)
Risk Assessment With Prior Test Results—Asymptomatic, Prior Coronary Calcium Agatston Score
26. ● Agatston score less than 100 I (1)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery—Low-Risk Surgery
28. ● Preoperative evaluation for noncardiac surgery risk assessment
● Minor or intermediate clinical risk predictors
I (1)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery—Intermediate-Risk Surgery
29. ● Poor exercise tolerance (less than or equal to 4 METs)
● Minor or no clinical risk predictors
I (2)
Risk Assessment: Preoperative Evaluation for Noncardiac Surgery—High-Risk Nonemergent Surgery
32. ● Asymptomatic up to 1 year after normal catheterization, noninvasive test, or previous
revascularization
I (1)
Risk Assessment: Following Acute Coronary Syndrome—Asymptomatic Post-Revascularization (PCI or CABG)
34. ● Routine evaluation prior to hospital discharge I (1)
Risk Assessment: Post-Revascularization (PCI or CABG)—Asymptomatic
36. ● Less than 5 years after CABG I (2)*
39. ● Asymptomatic (e.g., silent ischemia) prior to previous revascularization
● Less than 2 years after PCI
I (3)*
40. ● Symptomatic prior to previous revascularization
● Less than 2 years after PCI
I (2)
Stress Study for Hemodynamics (Includes Doppler During Stress)—Valvular Stenosis
46. ● Severe aortic or mitral stenosis I (2)
48. ● Severe AI or MR
● Symptomatic or with severe LV enlargement or LV systolic dysfunction
I (2)
Contrast Use–Use of Contrast With Stress Echo
50. ● Routine use of contrast
● All segments visualized on noncontrast images
I (1)
The ranking of this indication as inappropriate is different from that given to similar but not identical indications in previously published appropriateness criteria. The ratings were done in accordance
ith established ACCF methodology. Furthermore, the Technical Panel for each modality operated independently without allowance and with discouragement for intermodality comparisons. Discrepant
cores may be related to rating variability, differing Technical Panel composition, maturation of the appropriateness criteria process, or perceived differences in appropriateness.
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he appropriateness criteria in this report provide an
stimate of the reasonableness of the use of stress echocar-
iography for the particular clinical scenarios presented in
ach of the 51 indications considered. They are expected to
e useful for clinicians, health care facilities, and third-party
ayers engaged in the delivery of cardiovascular imaging.
xperience with already published appropriateness criteria
1,2) has shown their value across a broad range of situa-
ions, guiding care of individual patients, educating caregiv-
rs, and informing policy decisions regarding reimburse-
ent for cardiovascular imaging.
Appropriateness criteria represent the first component of
he chain of quality recommended for cardiovascular imag-
ng (11). After ensuring proper test selection, the achieve-
ent of quality in imaging includes adherence to best
ractices in image acquisition, image interpretation, and
esults communication, as well as incorporation of findings
nto clinical care. All components are important for optimal
atient care, although not all are addressed in this report.
he development of appropriateness criteria and their
anking by the Technical Panel assumes that other quality
tandards are adequately met. It also is assumed that when
onsidering the appropriateness of ordering a repeat or
nnual test that the prior image and report can be obtained
nd are of sufficient quality as outlined above.
Although the appropriateness ratings reflect a general
xpert consensus of when stress echocardiography may or
ay not be useful for specific patient populations, physicians
nd other stakeholders should understand the role of clinical
udgment in determining whether to order a test for an
ndividual patient. For example, the rating of an indication
s inappropriate should not preclude a provider from per-
orming stress echocardiographic procedures when there are
atient- and condition-specific data to support that deci-
ion. Indeed this may be the correct clinical pathway if
upported by mitigating characteristics of the patient. Like-
ise, uncertain indications often require individual physi-
ian judgment and understanding of the patient to better
etermine the usefulness of a test for a particular scenario.
s such, the ranking of an indication as uncertain (score 4
o 6) should not be viewed as limiting the use of stress
chocardiography for such patients. Finally, there may be
linical situations in which the use of stress echocardiogra-
hy for an indication considered to be appropriate does not
lways represent reasonable practice, such as a patient in
hom another diagnostic imaging test might be scheduled
r has already been performed.
The indications contained in this report are purposefully
road to capture the range of situations in which clinicians
nd value in stress echocardiography information. However,
s with the appropriateness criteria for other imaging modal-
ties, they are not exhaustive because of the complexity and
umber of the potential clinical situations. For example, teither the use of stress echocardiography prior to organ
ransplantation nor all forms of perioperative echocardiography
ere included as separate indications but are assumed to be
overed by the more general perioperative guidelines (10).
Stress echocardiography tests, like many imaging tests,
ay provide additional useful information beyond the
rimary purpose outlined by the indication. The appropri-
teness criteria for stress echocardiography were not devel-
ped to quantify the incremental information obtained by
erforming the test for reasons beyond those stated in an
ndividual indication. For example, the additional informa-
ion available with a stress echocardiogram, including the
ssessment of resting ejection fraction or the identification
f concomitant valve disease, was not considered when
etermining the appropriateness rankings. Thus, members
f the Technical Panel were asked specifically not to
onsider implicit or additional information outside the
cope of an individual indication in their rankings. As such,
he entire list of indications from this document and those
ublished separately for transthoracic and transesophageal
chocardiography (12) should be reviewed to assess a
roader range of potential reasons for ordering a stress
chocardiogram for an individual patient.
In addition, panelists were asked specifically not to
onsider comparisons to other imaging procedures or other
ppropriateness criteria documents while completing their
ankings. While stress CT and MR are newer modalities
hich have not been extensively studied, stress echocardi-
graphy and stress SPECT MPI have similar bodies of
vidence to support their use. The overwhelming majority
f final ratings of stress echocardiography and stress
PECT MPI were concordant for similar clinical indica-
ions. However, a small number of the final scores and
ating categories reported in this document differ from those
reviously published for stress SPECT MPI. Readers
hould note, however, that the categorical summaries tend
o accentuate differences that sometimes are slight. For
xample, small fluctuations in a median rating (e.g., 4 vs. 3)
ill cause an indication to switch appropriateness categories
e.g., from uncertain to inappropriate).
There are several potential reasons for these discordant
ccurrences. The most likely reason for this is a simple
ariation in rating by the different panel members, whether
ue to composition, different levels of clinical experience, or
ifferent interpretations of data. The RAND process has
ocumented that the interpretation of the literature by
ifferent sets of experts can yield slightly different final
atings (4). For example, one panel may contain a slightly
igher percentage of “modality experts” than another panel.
he Appropriateness Criteria Task Force has subsequently
xamined this influence of specialty and made every effort to
rovide a balance of expertise. Another source of potential
ariation is timing. As appropriateness criteria gain more
xposure, Technical Panel members have greater familiarity
ith the indications and implementation requirements thanhe panels of prior modules. Inconsistency in wording of
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lear panels may have also contributed to differences in some
cenarios. For example, stress echocardiography indications
ombined CAD detection and risk assessment into single
ndications, whereas the criteria for stress SPECT separated
hese indications.
The indications were developed and rated prior to the
elease of the ACC/AHA 2007 Perioperative Guidelines
10). As such, in addition to the Online Appendix (http://
ontent.onlinejacc.org), the reader should refer to the 2007
ersion of the guidelines for further discussion of the use of
oninvasive testing prior to surgery.
There are many potential applications for appropriateness
riteria. Clinicians could use the ratings as a decision
upport or educational tool when ordering a test or provid-
ng a referral to another qualified physician. The criteria also
ay be used to facilitate discussion with referring clinicians
ho have patterns of ordering tests for inappropriate indi-
ations. Facilities and payers may choose to use the criteria
ither prospectively in the design of protocols, automated
rder entry, and pre-authorization procedures, or retrospec-
ively for quality reports. It is hoped that payers will use this
ocument as the basis to inform rational strategies to ensure
hat their members receive the highest-quality, cost-
ffective cardiovascular care.
As outlined in the original methodology by the ACCF
3), it is expected that services performed for appropriate
ndications will receive reimbursement. In contrast, services
erformed for inappropriate indications will likely require
dditional documentation to justify payment because of
nique circumstances or the clinical profile of the patient.
ayers should note that the Technical Panel and clinical
ommunity do not consider uncertain indications as those
hat should not be performed or reimbursed. Rather, the
ncertain indications are those where the opinions of the
anel vary and the data may be conflicting. In many of these
reas, additional research is clearly desirable. Indications
ith high clinical volume that are rated as uncertain identify
reas for increased focus and research.
When used to assess performance, appropriateness crite-
ia should be applied in conjunction with systems that
upport quality improvement. Ordering forms containing
ssential information for determining appropriateness along
ith periodic feedback reports to providers may help edu-
ate providers on their ordering patterns. Prospective pre-
uthorization procedures, if put in place, are most effective
nce a retrospective review has identified a pattern of
otential inappropriate use. Because the criteria are based on
urrent scientific evidence and the deliberations of the
echnical Panel, they should be used prospectively to
enerate future discussions about reimbursement, but
hould not be applied retrospectively to cases completed
rior to issuance of this report.
The primary objective of this report is to provide guid-
nce regarding the perceived suitability of stress echocardi-
graphy for diverse clinical scenarios. As with previous *ppropriateness criteria documents, consensus among the
aters was desirable, but any attempt to achieve complete
greement within this diverse panel would have been arti-
cial and not necessarily of clinical value. Two rounds of
atings with lively discussion between the ratings did lead to
ome consensus among panelists. However, further at-
empts to drive consensus would have diluted true differ-
nces in opinion among panelists and, therefore, was not
ndertaken.
Future research analyzing patient outcomes utilizing
ndications rated appropriate would help ensure the equita-
le and efficient allocation of resources for diagnostic
tudies. Review of medically necessary care may also im-
rove the understanding of regional variations in imaging
tilization. Further exploration of the indications rated as
uncertain” will help generate the data required to further
efine the appropriateness of stress echocardiography. Fi-
ally, it will be necessary to periodically assess and update
he indications and criteria as technology evolves and new
ata and field experience become available.
ppendix A: Stress Echocardiography
efinitions
etermining Pre-Test Probability of CAD
ngina: as defined by the ACC/AHA Guidelines on
xercise Testing (9)
Typical Angina (Definite) (13):
. Substernal chest pain or discomfort that is
. provoked by exertion or emotional stress and
. relieved by rest and/or nitroglycerin.
Atypical Angina (Probable): Chest pain or discomfort
that lacks one of the characteristics of definite or typical
angina (13).
onanginal Chest Pain: Chest pain or discomfort that
eets one or none of the typical angina characteristics (13).
hest Pain Syndrome or Anginal Equivalent: Any con-
tellation of symptoms that the physician feels may repre-
ent a complaint consistent with obstructive CAD. Exam-
les of such symptoms include, but are not exclusive to,
able A1. Pre-Test Likelihood of CAD in Symptomatic Patients
ccording to Age and Gender* (Combined Diamond/Forrester
nd CASS Data) (17,18)
Age
(Years)
Nonanginal
Chest Pain Atypical Angina Typical Angina
Men Women Men Women Men Women
0–39 4 2 34 12 76 26
0–49 13 3 51 22 87 55
0–59 20 7 65 31 93 73
0–69 27 14 72 51 94 86Each value represents the percentage with significant CAD on catheterization.
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alpitations, syncope, breathlessness, and jaw pain.
re-Test Probability of CAD: Once the physician deter-
ines the presence of symptoms that may represent ob-
tructive CAD (chest pain syndrome or anginal equivalent
resent), then the pre-test probability of CAD should be
etermined. There are a number of risk algorithms (14,15)
vailable that can be used to calculate this probability.
linicians should become familiar with those that pertain to
he populations they encounter most often. In scoring the
ndications, the following probabilities as calculated from
ny of the various available algorithms should be applied.
Low pre-test probability: Less than 10% pre-test proba-
bility of CAD
Intermediate pre-test probability: Between 10% and 90%
pre-test probability of CAD
able A2. Comparing Pre-Test Likelihoods of CAD in Low-Risk
ymptomatic Patients With High-Risk Symptomatic
atients—Duke Database (15)
Age
(Years)
Nonanginal
Chest Pain Atypical Angina Typical Angina
Men Women Men Women Men Women
5 3–35 1–19 8–59 2–39 30–88 10–78
5 9–47 2–22 21–70 5–43 51–92 20–79
5 23–59 4–25 45–79 10–47 80–95 38–82
5 49–69 9–29 71–86 20–51 93–97 56–84
ach value represents the percent with significant CAD. The first is the percentage for a low-risk,
id-decade patient without diabetes, smoking, or hyperlipidemia. The second is that of the same
ge patient with diabetes, smoking, and hyperlipidemia. Both high- and low-risk patients have
ormal resting ECGs. If ST-T-wave changes or Q waves had been present, the likelihood of CAD
ould be higher in each entry of the table.
able A3. Men: 10-Year CHD Risk According to Framingham R
reen indicates below average risk; violet, average risk; yellow, moderately above average risk;
ge for a nonsmoker, nondiabetic, with blood pressure less than 120/80 mm Hg, total cholester
nd greater than or equal to 55 mg/dl in women. †Number of points estimated from Table 4 of Grundy
nrecognized myocardial infarction, unstable angina, and CHD deaths. §Hard CHD includes all of the tHigh pre-test probability: Greater than 90% pre-test
probability
The method recommended by the ACC/AHA Guide-
ines for Chronic Stable Angina (16) is provided below as 1
xample of a method used to calculate pre-test probability
nd is a modification of a previously published literature
eview (17). Please refer to definitions of angina and Table
1. Please note that the following table only predicts
re-test probability in patients without other complicating
istory or ECG findings. History and electrocardiographic
vidence of prior infarction dramatically affect pre-test
robability. Detailed nomograms are available that incorpo-
ate the effects of a history of prior infarction, electrocar-
iographic Q waves, electrocardiographic ST- and T-wave
hanges, diabetes, smoking, and hypercholesterolemia (9)
Table A2 presents 1 example).
etermining Pre-Test Risk Assessment for
isk Stratification
isk Assessment
he rating sheets on risk assessment include indications in
atients with suspected CAD.
It is assumed that clinicians will use echocardiography
tudies in addition to standard methods of risk assessment
s presented in the AHA/ACC Scientific Statement: As-
essment of Cardiovascular Risk by Use of Multiple-Risk-
actor Assessment Equations (19). See the scientific state-
ent to determine Framingham Risk Score (Tables A3 and
4) to calculate CHD risk percentage. As noted in the
cientific statement, these scores should be modified on the
asis of additional relevant factors shown to affect risk such
core
d, high risk. Low-risk level is defined in the Framingham Report (21) as the risk of CHD at any
0 to 199 mg/dl, LDL-C 100 to 129 mg/dl, and HDL-C greater than or equal to 45 mg/dl in menisk S
and re
ol of 16et al. (19). ‡Total Coronary Heart Disease (Total CHD) includes angina pectoris, recognized and
otal CHD events except for angina pectoris. Adapted from (19).
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istory of premature CHD, ethnic characteristics (especially
outh Asians in the United States), and hypertriglyceride-
ia.
HD Risk‡
Based on the AHA/ACC Scientific Statement on Cardio-
ascular Risk Assessment [19])
CHD Risk–Low
Defined by the age-specific risk level that is below
average. In general, low risk will correlate with a 10-year
absolute CHD risk less than 10%.
CHD Risk–Moderate
Defined by the age-specific risk level that is average or
above average. In general, moderate risk will correlate
with a 10-year absolute CHD risk between 10% to 20%.
CHD Risk–High
Defined as a 10-year absolute CHD risk of greater
than 20% or the presence of diabetes mellitus.†
Grundy et al. (19) cite Framingham when assigning patients with diabetes mellitus
able A4. Women: 10-Year CHD Risk According to Framingham
reen indicates below average risk; violet, average risk; yellow, moderately above average risk;
ge for a nonsmoker, nondiabetic, with blood pressure less than 120/80 mm Hg, total cholester
nd greater than or equal to 55 mg/dl in women. †Number of points estimated from Table 4 of
nrecognized myocardial infarction, unstable angina, and CHD deaths. §Hard CHD includes allo a category of high short-term risk because these patients typically have multiple risk
actors and have poor prognoses if they develop CHD.
a
Pvaluating Perioperative Risk for
oncardiac Surgery§
ethod for Determining Perioperative Risk
Based on the recommendations from the ACC/AHA
erioperative Cardiovascular Evaluation for Noncardiac
urgery [20])
Review Figure A1, “Stepwise Approach to Preoperative
ardiac Assessment.” Based on the algorithm, once it is
etermined that the patient does not require urgent surgery,
nd that there has not been revascularization within the last
years, the clinician should determine the patient’s periop-
rative risk predictors (see definitions in the following text).
f major risk predictors are present, Figure A1 suggests
onsideration of coronary angiography and postponing or
anceling noncardiac surgery. Once perioperative risk pre-
ictors are assessed based on the algorithm, then the surgical
isk and patient’s functional status should be used to
stablish the need for noninvasive testing.
Definitions and algorithms cited were current at the time of the technical panel and
k Score
d, high risk. Low-risk level is defined in the Framingham Report (21) as the risk of CHD at any
0 to 199 mg/dl, LDL-C 100 to 129 mg/dl, and HDL-C greater than or equal to 45 mg/dl in men
t al. (19). ‡Total Coronary Heart Disease (Total CHD) includes angina pectoris, recognized and
otal CHD events except for angina pectoris. Adapted from (19).Ris
and re
ol of 16re those reviewed by the technical panel at time of rating. See 2007 ACC/AHA
erioperative Guidelines for updated content (10).
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i
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teps are discussed in the text. Definitions and algorithms cited were current at the time of the technical panel and are those reviewed by the technical panel at time of rat-
ng. See 2007 ACC/AHA Perioperative Guidelines for updated content (10). *Subsequent care may include cancellation or delay of surgery, coronary revascularization fol-
owed by noncardiac surgery, or intensified care. CHF  congestive heart failure; ECG  electrocardiogram; MET  metabolic equivalent; MI  myocardial infarction.
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Major risk predictors
Unstable coronary syndromes, decompensated HF, sig-
ificant arrhythmias, and severe valve disease.
Intermediate risk predictors
Mild angina, prior MI, compensated or prior HF, dia-
etes, or renal insufficiency.
Minor risk predictors
Advanced age, abnormal ECG, rhythm other than sinus,
ow functional capacity, history of cerebrovascular accident,
nd uncontrolled hypertension.
urgical Risk Categories
High-Risk Surgery–cardiac death or MI greater than 5%
Emergent major operations (particularly in the el-
derly), aortic and peripheral vascular surgery, prolonged
surgical procedures associated with large fluid shifts
and/or blood loss.
Intermediate-Risk Surgery–cardiac death or MI equal to
1% to 5%
Carotid endarterectomy, head and neck surgery, sur-
gery of the chest or abdomen, orthopedic surgery, pros-
tate surgery.
Low-Risk Surgery–cardiac death or MI less than 1%
Endoscopic procedures, superficial procedures, cata-
ract surgery, breast surgery.
CG–Uninterpretable
efers to ECGs with resting ST-segment depression
greater than or equal to 0.10 mV), complete left bundle-
ranch block, pre-excitation (Wolf-Parkinson-White syn-
rome), or paced rhythm.
ppendix B: Methods
anel Selection
takeholders were given the opportunity to participate in
he appropriateness criteria process by submitting nominees
rom their organizations through a Call for Nominations
eleased in the summer of 2006. From this list of nominees,
he Task Force selected panel members to ensure an
ppropriate balance with respect to expertise in the specific
odality, referring physicians, academic versus private prac-
ice, health services research, and specialty training.
evelopment of Indications
he process for creating a robust set of indications involved
onsulting current literature and previously published guide-t
As defined by the ACC/AHA Guideline Update for Perioperative Cardiovascular
valuation of Non-Cardiac Surgery (20).ines and clinical policy statements. The indications capture
he majority of scenarios faced by cardiologists or referring
hysicians, but are not meant to be inclusive of all potential
ndications for which a stress echocardiography imaging
tudy may be performed. Review was done by the Task
orce, including additional comments from external review-
rs. As a result of the meeting of the Technical Panel prior
o the second round of rating, a number of the indications
ere clarified and modified. A final set of indications
omprised the list of possible clinical scenarios that were
ated for appropriateness by the panelists and compiled for
his report.
ating Process
he Technical Panel was instructed to follow the process
utlined in the document, “ACCF Proposed Method for
valuating the Appropriateness of Cardiovascular Imaging”
3). The appropriateness method combines expert clinical
udgment with the scientific literature in evaluating the
enefits and risks of medical procedures. Each panel mem-
er has equal weight in producing the final result for the set
f indications they are asked to rate and the method does
ot force consensus.
The rating process includes a modified Delphi process
nvolving 2 rounds of ratings and an intervening face-to-
ace meeting. At the face-to-face meeting, each panelist
eceived a personalized rating form that indicated his or her
ating for each indication and the distribution of de-
dentified ratings of other members of the panel. In addi-
ion, the moderator received a summary rating form with
imilar information (including panelist identification), along
ith other statistics that measured the level of agreement
mong panel members. A measure of the level of disagree-
ent was applied to each score after both the first and
econd round scoring was completed. This project employed
he BIOMED Concerted Action on Appropriateness def-
nition for a panel size of 14 to 16. As defined in the
AND/UCLA manual (4) upon which the ACCF ratings
ethod is based, the BIOMED rule for agreement () is
hat no more than 4 panelists rate the indication outside the
-point region containing the median; for disagreement
), at least 5 panelists rate in each extreme rating region
i.e., 1 to 3 and 7 to 9). Measures of agreement and the
ispersion of ratings (mean absolute deviation from the
edian) may highlight areas where definitions are not clear
r ratings are inconsistent, where panelist perceptions of the
average” patient may differ, or where various specialty
roups or individual panelists may have differences of
linical opinion. In cases of obvious disagreement or outlier
cores, the indication was highlighted in a summary table
nd identification of the outlier raters brought to the
ttention of the moderator. This information was used by
he moderator to guide the panel’s discussion.
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he ACCF and its partnering organizations rigorously
void any actual, perceived, or potential conflicts of interest
hat may arise as a result of an outside relationship or
ersonal interest of a member of the Technical Panel.
pecifically, all panelists are asked to provide disclosure
tatements of all relationships that may be perceived as real
r potential conflicts of interest. These statements were
eviewed by the ACCF Appropriateness Criteria Task
orce, discussed with all members of the Technical Panel at
he face-to-face meeting, and updated and reviewed as
ecessary. A table of disclosures of the Technical Panel and
ask Force Members can be found in the Appendix D.
iterature Review
he Technical Panel members were asked to refer to the
elevant guidelines for a summary of the relevant literature,
uideline recommendation tables, and reference lists pro-
ided for each indication table when completing their
atings (Online Appendix at http://content.onlinejacc.org).
astly, they were provided Web links to the previously
ublished materials pertaining to the appropriateness crite-
ia work (1–3).
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ijoy Khandheria, MD, FASE, FACC–Professor of Med-
icine and Chair, Division of Cardiovascular Disease,
Mayo Clinic, Scottsdale, AZ
aymond F. Stainback, MD, FACC, FASE–Assistant
Professor of Medicine (Clinical), Baylor College of
Medicine; Medical Director, Noninvasive Cardiac Im-
aging and Adult Echocardiography Laboratories, St.
Luke’s Episcopal Hospital, Texas Heart Institute; Part-
ner, Hall-Garcia Cardiology Associates, Houston, TX
eil J. Weissman, MD, FACC, FASE–Professor of Med-
icine, Georgetown University Medical Center, Wash-
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vascular Research Institute, Washington Hospital
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tress Echocardiography Technical Panel
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of the Technical Panel–Professor of Medicine and
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